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Abstract Metabolic reprogramming is a hallmark of cancer
cells and contributes to their adaption within the tumour mi-
croenvironment and resistance to anticancer therapies. Re-
cently, glycogen metabolism has become a recognised feature
of cancer cells since it is upregulated in many tumour types,
suggesting that it is an important aspect of cancer cell patho-
physiology. Here, we provide an overview of glycogen me-
tabolism and its regulation, with a focus on its role in meta-
bolic reprogramming of cancer cells under stress conditions
such as hypoxia, glucose deprivation and anticancer treat-
ment. The various methods to detect glycogen in tumours
in vivo as well as pharmacological modulators of glycogen
metabolism are also reviewed. Finally, we discuss the thera-
peutic value of targeting glycogen metabolism as a strategy
for combinational approaches in cancer treatment.
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Glycogen metabolism
Glycogen is the storage form of glucose in cells and is essen-
tial for energy supply and glucose homeostasis. The discovery
of glycogen in liver in 1857 is attributed to Claude Bernard
[1]. The general mechanism of glycogen synthesis and degra-
dation is the same in all tissues, whilst the regulation of gly-
cogen metabolism differs.
Glygogen synthesis is performed in the cytosol from extra-
cellular glucose transported into the cells through glucose
transporters or from an indirect pathway where lactate and
amino acids can be used. Figure 1 provides a general schemat-
ic presentation of the glycogen pathway. The first step of gly-
cogen synthesis consists of autoglucosylation of the core pro-
tein, glycogenin, which provides an oligosaccharide primer.
To this oligosaccharide primer, glycogen synthase elongates
the glucose chain by attaching uridine diphosphate (UDP)-
glucose units through α-1,4 glycocidic linkage. Next, when
the elongating chain reaches around 12 glucose units, then a
glycogen branching enzyme transfers a chain of seven units to
an adjacent chain via α-1,6 glycosidic bond. Glycogen syn-
thase elongates the glycogen chain, whilst the glycogen
branching enzyme produces new branches.
Glycogen breakdown requires synchronous activities of
glycogen phosphorylase and the bifunctional glycogen
debranching enzyme. Glycogen phosphorylase, which is the
rate-limiting enzyme of glycogenolysis, cleaves the α-1,4
linkage to remove glucose residues from the glycogen chain
as glucose 1-phosphate. Further, when four glucose units re-
main before the branching point, the bifunctional debranching
enzyme using the transferase activity will transfer the three
glucose residues to an adjacent branch of the glycogen chain.
After that, through the glucosidase activity, the debranching
enzyme cleaves the α-1,6 linkage to release a free glucose
from the branch point. Glycogen phosphorylase continues to
the cleavage of glucose residues from the glycogen chain,
producing glucose 1-phosphate.
The present review will address the role of glycogen me-
tabolism in cancer and whether this metabolic pathway could
be druggable and have therapeutic value combined with other
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anticancer therapies. Also, the reader is referred to earlier re-
views on glycogen metabolism in more detail in normal and
pathological conditions, for additional background.
Glycogen biosynthesis: key proteins and enzymes
Glycogenin
Glycogen biosynthesis requires the protein glycogenin,
which is the core protein at the centre of glycogen gran-
ules. Glycogenin is an auto-glucosylating protein, which
catalyses and initiates the formation of a short glucose
polymer, leading to an α-1,4-linked chain of approximately
8–12 glucose residues [2, 3].
Elongation and branching of the glucose polymer by gly-
cogen synthase and branching enzyme follow this reaction
[4]. In humans, glycogenin exists in two isoforms, GYG1
(39 kDa, 350 aa) which is expressed predominately in skeletal
muscle and GYG2 which is expressed in liver, heart and pan-
creas (55 kDa, 501 aa). Glycogenin contains a conserved do-
main of approximately 250 amino acids at its N-terminus, that
is required for uridine diphosphate glucose binding and catal-
ysis, and a highly conserved domain of 30–35 amino acids at
its C-terminus which is required for glycogen synthase bind-
ing [5]. Glycogenin 1 deficiency causes a muscle glycogen
storage disease, type XV [6]. Recently, Malfatti et al. de-
scribed a new muscle glycogen storage disorder characterised
by polyglucosan bodies that is due to either deficiency of
glycogenin-1 or impaired interaction of glycogenin-1 with
glycogen synthase [7]. Polyglucosan refers to abnormal
amylopectin-like polysaccharides, which are less branched
than normal glycogen and may aggregate into polyglucosan
bodies [8]. Unlike normal glycogen, polyglucosan bodies are
Fig. 1 Key pathways of glycogen synthesis and metabolism. Glycogen
synthesis requires formation of UDP-glucose from glucose-1-phosphate
and UTP to be catalysed UDP-glucose pyrophosphorylase. Glycogenin
initiates the first step of glycogen synthesis by self glycosylation of a short
8–12 glucose oligosaccharide primer. Glycogen synthase (GYS)
elongates the glucose oligossacharide primer, which utilises UDP-
glucose as the glucosyl donor. Glycogen branching enzyme (GBE)
catalyses the transfer of α-1,4-linked glucose units from the outer ‘non-
reducing’ end of a growing glycogen chain into an α-1,6 position of the
same or neighbouring chain. Glycogen degradation requires the
synchronous activation of the glycogen phosphorylase and the
bifunctional enzyme glycogen debranching enzyme. Glycogen
phosphorylase releases glucose-1-P from the terminal alpha-1,4-
glycosidic bond, and the glycogen debranching enzyme catalyses the
removal of the branches. DBE transfers three glucose blocks to another
glycogen chain, and then hydrolytically cleaves the remaining glucose of
the branch, generating free glucose. Glycogen-derived glucose-1-P and
free glucose can enter the glycolytic or the pentose phosphate pathway
(PPP)
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resistance to digestion with α-amylase [9]. Polyglucosan bod-
ies have a fibrilar structure under electron microscopy and can
be seen also in normal ageing in heart and central nervous
system. Similar polyglucosan structures are also seen in defi-
ciency of the glycogen branching enzyme deficiency mice
[10].Mutations in nine human genes, GYG1, GBE1, RBCK1,
PFKM, EPM2A, EPM2B, PRDM8, PRKAG2 and GYS1, are
known to be associated with polyglucosan structures [6]. It is
clear that different forms of glycogen can be produced and that
glycogenin is important for normal and functional glycogen
particles. Whether glycogenin is important as therapeutic tar-
get in cancer is unknown.
Glycogen synthase
In mammals, glycogen synthase exists in two isoforms, the
glycogen synthase 1 (GYS1; 84 kDa, 737 aa), which is
expressed in skeletal muscle and other tissues, and the
GYS2 (81 kDa, 703 aa), which is expressed predominately
in the liver. The liver isoform (GYS2, 81 kD) is about 70 %
identical to the muscle isoform (GYS1, 84 kD) and has several
phosphorylation sites near the N- and C-terminus [11]. GYS1
and GYS2 deficiency cause the muscle and liver glycogen
storage disease type 0, respectively. Symptoms involved with-
in those deficiencies are inability to form glycogen, muscle
weakness, arrhythmia, sudden death and hypoglycaemia. Gly-
cogen synthase exists in a phosphorylated (glycogen synthase
b) and a dephosphorylated form (glycogen synthase a). Phos-
phorylation causes inactivation of the enzyme by decreasing
the affinity for UDP-glucose [12, 13], whilst glucose-6-
phosphate (G6P) is an allosteric activator of the phosphorylat-
ed form [14, 15] (Figs. 2 and 3). The crystal structure of the
glycogen synthase in yeast was reported in 2010 in the pres-
ence and absence of the allosteric activator G6P [16]. Glyco-
gen synthase exists as a tetrameric form and has direct inter-
action with glycogenin and glycogen branching enzyme in
order to facilitate glycogen synthesis [5].
G lycogen syn thase i s r egu la t ed by mu l t ip l e
phosphorylation/dephosphorylation events and by allosteric
effectors (Figs. 2 and 3). Further, these sites on glycogen syn-
thase are phosphorylated in vitro by kinases such as protein
kinase A, phosphorylase kinase, protein kinase C, protein ki-
nases CK1 and CK2, glycogen synthase kinase 3 and AMP-
activated protein kinase [12, 13].
Muscle glycogen synthase (GYS1) has nine well-
characterised phosphorylation sites (rabbit/mouse 7/8, 10/11,
640/641, 644/645, 648/649, 652/653, 656/657, 697/698 and
710/711), whilst the liver isoform GYS2 has seven conserved
phosphorylation sites and lacks the last two 697/698 and 710/
711, which mainly regulated by protein kinase A in skeletal
muscle [17, 18]. Phosphorylation and inactivation of the gly-
cogen synthase occurred by various protein kinases (Fig. 3).
Phosphorylation at Ser7/8 occurs by protein kinase A (PKA;
also phosphorylates at Ser697/698 and Ser710/711), protein kinase
C (PKC; also phosphorylates at Ser697/698), phosphorylase
kinase (PhK), calmodulin-dependent kinase II (CaMK II; also
phosphorylates at Ser710/711), mitogen-activated protein ki-
nase (MAPK)-activated protein kinase 2 (MAPKPAK2) and
AMP-activated protein kinase (AMPK) [19]. Hierarchical
phosphorylation of Ser7/8 and Ser10/11 occurred also via casein
kinase 1 (CK1).
Glycogen synthase kinase 3 (GSK3) acts predominantly in
the phosphorylation of the glycogen synthase at different sites
such as Ser640/641, Ser644/645, Ser648/649 and Ser652/653 [19].
Casein kinase 2 (CK2) phosphorylates glycogen synthase at
Ser656/657 to initiate and create the recognition motif for the
GSK3 to phosphorylate glycogen synthase at Ser640/641,
Ser644/645, Ser648/649 and Ser652/653. Also, other protein kinases
such as dual-specificity tyrosine phosphorylated and regulated
protein kinase (DYRK) and Per-Arnt-Sim domain kinase
(PASK) have been reported to directly phosphorylate GS at
Ser640/641 [20, 21] and p38 MAPK Ser644/645 and Ser648/649
[22]. Mutational studies have confirmed that phosphorylation
sites at Ser7/8, Ser640/641 and Ser644/645 are key regulators of
the glycogen synthase activity [23, 24].
Muscle contraction stimulates GYS1 in order to rapidly
restore glycogen content, which is used for energy supply
through activation of glycogen phosphorylase. This occurs
via dephosphorylation of GYS1 that is protein kinase B
(PKB)/GSK3 independent [25] and dependent on the muscle
specific protein phosphatase PP1G [26].
G6P allosterically activates glycogen synthase through the
binding of the arginine-rich domain (Arg579–591). High con-
centrations of G6P can restore the activity of glycogen syn-
thase, even if the enzyme is fully phosphorylated [27]. G6P
regulates the activity of glycogen synthase not only by allo-
steric activation but also bymaking the protein a more suitable
substrate for dephosphorylation by protein phosphatase 1
(PP1) [14]. Dephosphorylation of glycogen synthase is
catalysed by PP1 bound to glycogen targeting subunits
(PPP1R3), which remove a phosphate group by hydrolysis
[28, 29]. Insulin activates the insulin receptor tyrosine kinase,
which further activates the phosphatidylinositol 3-kinase
(PI3K) and Akt pathways and stimulates glycogen synthesis
via inhibition of glycogen synthase 3 (GSK3) and also by
activation of the PP1 (Fig. 2) [30, 31]. Moreover, insulin stim-
ulates glucose uptake via translocation of glucose transporters
to the plasma membrane [30, 31]. Hypoxia and glucose star-
vation regulate the activity of glycogen synthase via the in-
duction of the protein phosphatase 1, regulatory subunit 3
(PPP1R3C) [32, 33].
Glycogen branching enzyme
The glycogen branching enzyme GBE1 (80 kDa, 702 aa) ca-
talyses the transfer of α-1,4-linked glucose units from the
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outer ‘non-reducing’ end of a growing glycogen chain into an
α-1,6 position of the same or neighbouring chain. Together,
glycogen synthase and glycogen branching enzyme are both
required for the globular and branched structure of glycogen,
which is essential to increase its solubility by creating a hy-
drophilic surface and reduce the osmotic pressure within cells
[34, 35]. The crystal structure and function of the human
GBE1 have been described recently [36].
Glycogen branching enzyme deficiency is associated with
an accumulation of insoluble polysaccharide particles, which
lead to the autosomal recessive glycogen storage disorder type
IV. Glycogen storage disorder type IV (GSDIV) is a severe
disorder with variable onset age and clinical severity, includ-
ing a classical hepatic form in neonates and children that pro-
gresses to cirrhosis (Andersen disease) [37], a neuromuscular
form classified into four subtypes (perinatal, congenital, juve-
nile and adult onset) [38] and a late-onset adult polyglucosan
body disease, a neurological disorder affecting mainly the
Ashkenazi Jewish population [39]. The mechanism by which
the glycogen branching enzyme orchestrates the glycogenin
and glycogen synthase to form functional glycogen particles is
not understood.
Protein phosphatase 1 and glycogen targeting subunits
Protein phosphatase 1 (PP1; 35–38 kDa) is an essential eu-
karyotic protein serine/threonine phosphatase that regulates
different cellular functions such as, cell division, glycogen
metabolism, muscle contraction and protein synthesis [40,
41]. In mammals, there are three genes encoding the PP1
catalytic subunit, PP1α, PP1β/δ and PP1γ. The PP1γ gene
encodes two proteins, PP1γ1 and PP1γ2, which arise through
alternative splicing [40, 41].
Fig. 2 Regulation of glycogen metabolism by glycogen synthase and
glycogen phosphorylase. Glucagon, epinephrine, physical activity
induces cAMP via cognate receptors. cAMP activates protein kinase A
(PKA). PKA converts the inactive phosphorylase kinase (PhK) to an
active form. Also, PKA converts the active form of glycogen synthase a
(GSa) to an inactive form of glycogen synthase b (GSb). The active PK
phosphorylates and activates glycogen phosphorylase a (GPa). The
protein phosphatase 1 (PP1) conjugated to the protein target to
glycogen subunits (RRR1R3 family) dephosphorylates GPa and active
PK and forms the less active GPb and inactive PK. GPa catalyses the
degradation of glycogen to G1P and also inhibits the glycogen PP1which
converts the inactive glycogen synthase (GSb) to active glycogen
synthase a (GSa). PP1 is regulated by another inhibitor called
phosphoprotein phosphatase inhibitor (PI-1). PI-1 can be
phosphorylated (activated) by PKA. PKA phosphorylation turns on GP
and turns off GS. It also activates PI-1, which turns off the phosphatase
(PP1) that would normally activate GS by dephosphorylating it. Insulin
activates the insulin receptor tyrosine kinase, which further activates the
PI3K and Akt and stimulates glycogen synthesis via inhibition of
glycogen synthase 3 (GSK3), also activation of the PP1 and decrease of
cAMP. Insulin stimulates the glucose uptake via translocation of glucose
transporters to the plasma membrane. Green text and lines represent
activation, whilst red text and lines represent inactivation
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Glycogen targeting subunits, PPP1R3 family proteins,
have a major role in recruiting PP1 to glycogen and increasing
the specific activity of PP1 towards specific glycogen en-
zymes such as glycogen synthase and glycogen phosphory-
lase [40–42]. One of the major functions of the PP1-PPP1R3
complex is the dephosphorylation and the activation of the
glycogen synthase. There is a short conserved binding motif,
the RVxFmotif, in glycogen targeting subunits, which interact
with the small hydrophobic groove on the surface of the pro-
tein phosphatase 1 [40–42].
At least seven genes encode the glycogen targeting sub-
units. The PPP1R3A GM/RGL (124 kDa), gene that encodes
the muscle specific subunit; the PPP1R3B GL (33 kDa), gene
that encodes the liver and muscle subunits; the protein target
to glycogen (PTG) or Gc/R5/PPP1R3C (36 kDa), which is
highly expressed in skeletal and cardiac muscle and liver;
the GD/R6 PPP1R3D (33 kDa) and GE PPP1R3E (31 kDa)
which are most expressed in human skeletal muscle and heart
[28]; the GF PPP1R3F (79 kDa), which is expressed at high
levels in the brain [43]; and the GG PPP1R3G (38 kDa), which
is expressed at high levels in the liver [44]. The N-terminal
region of the glycogen targeting subunit is required for bind-
ing to PP1; the central region is required for binding to glycogen;
and the C-terminal region is required for binding to glycogen
phosphorylase, glycogen synthase and phosphorylase kinase.
Overexpression of protein target to glycogen subunit
(PPP1R3C) in liver or fat cells significantly increases the gly-
cogen levels [45, 46]. The three hepatic glycogen target sub-
units are much smaller compared to the muscle type
PPP1R3A subunit, and this is due to their lack of a domain
for interaction with the endoplasmic reticulum [29]. Three
types of mechanism contribute to the glycogenic effects of
the glycogen targeting subunits: (i) dephosphorylation of gly-
cogen phosphorylase (inactivation) and glycogen synthase
(activation), (ii) enhanced targeting of glycogen synthase
and glycogen phosphorylase to the glycogen particle and
(iii) stabilisation of glycogen synthase protein [47].
Recently, the glycogen target subunits have emerged as
important components of glycogen metabolism. However,
future research needs to highlight their importance in nor-
mal cell physiology and cancer and whether there is any
therapeutic value for anticancer therapies. Why some tis-
sues expressed more than one isoform and their effect on
glycogen regulation under different metabolic stresses remain
unclear. In hepatocytes, both PPP1R3B and PPP1R3C are
induced in response to insulin, whilst PPP1R3G is repressed
by insulin and induced by glucagon and glucocorticoids [44,
48]. Furthermore, the exact function of the glycogen targeting
subunits as a sensor to orchestrate the interactions between the
glycogen particles, glycogen enzymes and other enzymes
Fig. 3 Regulation of glycogen phosphorylase and glycogen synthase. a
Glycogen phosphorylase is controlled by phosphorylation and allosteric
interactions. Glycogen phosphorylase convert to GPa by phosphorylation
via phosphorylase kinase (PhK), whilst dephosphorylation via protein
phosphatase 1 conjugated to protein glucogen target subunits (PPP1R3-
PP1) turns back to GPb. GPa and GPb exist in equilibrium between a
more active R state(R—relaxed) and less active/inactive T state (T—
tense). Under allosteric control, AMP converts the inactive T states
(GPa and GPb) to R states. Allosteric inhibitors such as ATP, glucose,
glucose-6-phosphate, caffeine and indole carboxamides can alter the
equilibrium back to the inactive T states of GP. b Glycogen synthase
kinase 3 (GSK3), protein kinase A (PKA), protein kinase C (PKC),
calmodulin-dependent protein kinase II (CaMKII), AMP-activated
protein kinase (AMPK), casein kinase 1 (CK1), casein kinase 2 (CK2)
and phosphorylase kinase (PhK) phosphorylate inactivate glycogen
synthase via phosphorylation in different sites. Protein phosphatase 1
conjugated to protein target to glycogen subunits (PPP1R3-PP1)
dephosphorylates the GSb and converts to active GSa form. Also, the
ATP, glucose, glucose-6-phosphate and caffeine activate the GS, whilst
calcium and cAMP deactivate the GS. Green text and lines represent
activation, whilst red text and lines represent inactivation
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such as glucokinase, glucose-6-phosphatase, is not well
understood.
Glycogen degradation pathways
Glycogen degradation can occur through two different path-
ways, the cytosolic and the autophagy-lysosomal pathway
(Fig. 4). In the cytosol, glycogen degradation is mediated
through two enzymes, glycogen phosphorylase and glycogen
debranching enzyme. Whilst in the autophagy and lysosomal
pathways, this process is mediated via the enzyme alpha acid
glucosidase.
Glycogen phosphorylase
Gycogen phosphorylase (GP) is the rate-limiting enzyme and
in mammals comprises three isoforms, liver (PYGL, 97 kD),
muscle (PYGM, 97 kD) and the brain (PYGB, 96.6 kD). For
simplicity, hereafter glycogen phosphorylase will be referred
to as GP for all isoforms. The liver enzyme serves the
glycaemic demands of the body in general, whereas the brain
and muscle isoenzymes supply glucose 1-phosphate just those
tissues. Glycogen phosphorylase uses inorganic phosphate Pi
to split glucose as glucose 1-phosphate from the polysaccha-
ride chains of glycogen.
GP has an essential cofactor, pryridoxal phosphate
(PLP), and is regulated by allosteric effectors and by
phosphorylation of a single serine residue at the N-terminus
[12, 13, 49–51]. Phosphorylation at serine-14 of glycogen
phosphorylase b (GPb, less active) to glycogen phosphorylase
a (GPa, active) is catalysed by phosphorylase kinase (PhK),
which is activated by cAMP-dependent protein kinase A and
increased levels of calcium [12, 13, 49–51]. GPs are dimers of
two identical monomers, and allosteric effectors bind to five
regulatory sites in each monomer, catalytic site (C site binds
glucose, glucose 1-phosphate and inorganic phosphate), the
purine nucleotide inhibitor or caffeine-binding site located
near the active site, an AMP allosteric site that also bind
ATP and G6P, glycogen site (G site) and the indole site that
binds indole carboxamide ligands [12, 13, 49, 50]. PP1 in
conjugation with the glycogen target subunit family proteins
(PPP1R3 family) dephosphorylates the GPa to the inactive
form, GPb. Both forms of GP can be found in the T (tense
state) and R states (relaxed state), where T is the inactive state
because it has a low affinity for substrate and R is the active
state, given its greater affinity for substrate [12, 13, 49–51].
Phosphorylation and allosteric ligands (AMP,
inorganic phosphate and glucose 1-phosphate) stabilise
the R state, whilst glucose, ATP, purine nucleosides and
G6P stabilise the less active T state (Fig. 3). Moreover,
glucose and other ligands that stabilise the T state pro-
mote the dephosphorylation of the GPa to GPb by PP1.
The phosphorylation control of GP is a response to
messages from the extracellular environment, signalled
by hormones, whilst allosteric control is a response to
intracellular sensors of the cell metabolic status [12, 13,
49, 50]. During physical activity, hormonal stimulation
(glucagon and epinephrine) activates the enzyme phos-
phorylase kinase, which in turn phosphorylates and con-
verts the less active form GPb into the more active
form, GPa (Fig. 2) [12, 13, 49, 50]. A recent discovery
is that glycogen phosphorylase is negatively regulated
via acetylation. Acetylation of lysine 470 and 796
Fig. 4 Glycogen degradation pathways. Glycogen can be degraded via
two pathways. Glycogen phoshorylase and glycogen debranching
enzyme produce glucose-1-phosphate (around 90 %) and free glucose
(around 10 %) which converted to glucose-6-phosphate and enters
glycolysis and TCA cycle. Autophagy-dependent glycogen degradation
is very important in the newborns and produces free glucose via the
lysosomal 1,4-α-glucosidase activity
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inhibited glycogen phosphorylase activity and enhanced
its interaction with PPP1R3C-PP1, thereby promoting
glycogen phosphorylase dephosphorylation [52]. Acety-
lation of glycogen phosphorylase was low in the fasted
state, and it was increased by high glucose and insulin,
whilst exposure of cells to glucagon had the converse
effect and promoted deacetylation [52].
Deficiency in muscle glycogen phosphorylase PYGM
causes a glycogen storage disease type V (also known as
GSDVor McArdle disease). People with GSDV typically ex-
perience muscle fatigue and pain and sometimes severe symp-
toms such as rhabdomyolysis during prolonged or intense
exercise. Deficiency in liver glycogen phosphorylase PYGL
causes inability to break down liver glycogen and a glycogen
storage disease type VI (also known as GSDVI or Hers dis-
ease). People with GSDVI have symptoms such as hepato-
megaly, growth retardation, ketotic hypoglycaemia and post-
prandial lactic acidosis.
Glycogen debranching enzyme
The glycogen debranching enzyme amylo-α-1,6-glucosidase,
4-α-glucanotransferase (AGL) (174.76 kDa, 1532 aa) binds to
glycogen through its C-terminal domain and possesses two
different independent catalytic activities, which occur at dif-
ferent sites on the protein [53–55].
Glycogen phosphorylase is responsible for the cleavage of
the α-1,4 glycocidic bonds and release G1P monomers that
can further metabolise. When glycogen phosphorylase digests
a glycogen branch down to four glucose residues, it will not be
able to cleave residues further along or break α-1,6 glycocidic
bonds at glycogen branch points.
Glycogen debranching enzyme assists the further cleavage
of the glucose residues. First, via the 4-α-D-glucanotransferase
or glucosyltransferase activity transfers/relocates the three
glucose residues from the four-residue glycogen branch to a
nearby branch. This leaves one glucose unit joined to the
glucose chain branch point through anα-1,6-glycosidic linkage
[53–55]. Second, via the amylo-α-1,6-glucosidase activity
cleaves the remaining alpha-1,6 linkage and produces free
glucose and a linear of glycogen [53–55].
Deficiency in glycogen debranching enzyme results in gly-
cogen storage disease type III (Cori’s disease) with an accu-
mulation of abnormal glycogen with short outer chains. It is
clinically characterised by hepatomegaly, hypoglycaemia,
short stature and variable myopathy. Glycogen storage disease
type III includes different forms. GSD type 3A patients lack
glycogen debranching enzyme activity in both liver and mus-
cle, whilst GSD type 3B patients are enzyme deficient in liver
only. In rare cases, selective loss of only one of the two
debranching activities, glucosidase or transferase, results in
GSD type 3C or type 3D, respectively [56].
Autophagy and lysosomal pathways
Autophagy is a fundamental intracellular process for the
degradation and recycling of cytoplasmic constituents
through lysosomes. The recycled materials are major in-
puts for multiple anabolic and biosynthetic pathways in
cells. Glycogen autophagy (glycophagy) is the autopha-
gic sequestration and degradation of glycogen to support
glucose homeostasis [57, 58]. Glycogen autophagy is a
very important process for the production of glucose of
newborn animals [57, 59–61]. In newborns, glycogen
autophagy is induced by glucagon during post-natal
hypoglycaemia and is inhibited by insulin and parenteral
glucose [57].
An accumulation of autophagic and lysosomal vesicles
containing glycogen has been observed in several myopathies
such as Pompe disease, Danon disease, infantile autophagic
vacuolar myopathy and drug-induced vacuolar myopathies
caused by treatment with chloroquine or hydroxychloroquine
[62, 63]. However, it remains unclear how glycogen me-
tabolism connects to the pathology of the diseases. Mice
lacking the lysosomal enzyme acid α-glucosidase GAA−/−
in skeletal muscle, a model for Pombe disease, have
shown massive accumulation of glycogen in lysosomes,
autophagosomes and late endosomes which are major
characteristics of the diseases [64]. In the same model,
loss of Atg5 diminished the glycogen built up in
autophagosomes but make the clinical phenotype worse
[65]. Further, loss of the autophagy protein Atg7 de-
creased glycogen by 50–60 %, whilst enzyme replacement
therapy of GAA normalised the glycogen levels in the
autophagy deficient mice, an outcome not observed in
Pompe mice with genetically intact autophagy [66].
Another study found that CQ-induced myopathy can be
improved by decrease of autophagy or glycogen synthesis,
the latter possibly due to a direct role of glycogen syn-
thase in regulating autophagy through its interaction with
the Atg8 family [67]. More recently, a study by Farah
et al. [68] found that pharmacological induction of autoph-
agy corrects hepatic glycogen and lipid accumulation in
glucose-6-phosphatase deficiency mice G6Pase−/−, an ani-
mal model of von Gierke’s disease or GSDIa, suggesting
the importance of autophagy in glycogen and lipid metab-
olism as a new therapeutic strategy in GSDIa.
The exact mechanism by which glycogen sequestered
by autophagy and transferred to lysosomes and whether
any defects on that process lead to diseases remain un-
known. GYS1 has been identified as potential interactor
of GABARAPL1, using mass spectroscopy [69]. More
recently, Zirin et al. [67] identified three putative LIR
motifs conserved between Drosophila melanogaster gly-
cogen synthase and its mammalian orthologs, VAHFHE
(residues 187–192), EFQNL (residues 303–307) and
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DWRTL (residues 608–612), which interact with Atg8
under starvation conditions. In this respect, the metabol-
ic interaction and key protein players between autophagy and
glycogen particles need to be further investigated.
Liver
The glycogen content in liver is around 100 g in 1.5-kg tissue
[70]. The liver maintains normal blood glucose levels by rapid
clearance of glucose from the portal vein in the absorptive state
after ameal and by controlling production of glucose in the post-
absorptive state at a sufficient rate to maintain euglycaemia [12].
The liver accumulates glycogen in large amounts and releases it
slowly to maintain blood sugar levels. Glycogen synthesis is
performed in the cytosol from extracellular glucose transported
into the cells through glucose transporters (direct pathway) or
from gluconeogenic substrates, such as lactate and amino acids
(indirect pathway). The indirect pathway occurs mainly in the
liver, following either the intrahepatic or extrahepatic conver-
sion of gluconeogenic precursors into glucose [71].
Muscle
In humans, 80 % of glycogen stored in skeletal muscle just
because skeletal muscle accounts for 40–50 % of body
weight, whilst the concentration of the glycogen is around
80–150 mmol/kg. Each glycogen granule contains approxi-
mately 30,000 glucose residues with numerous non-reducing
ends for rapid access to glucose [72]. In skeletal muscle, up to
90% of glucose load is converted to glycogen and the amount
of glycogen stored is higher in type II fibres (fast switch)
compared with the type I (slow twitch). In skeletal muscle,
distinct pools of glycogen with distinct characteristics and
functions in muscle contractility have been identified [73,
74]. Electron microscopy studies have shown that glycogen
pools localised in the subsarcolemmal, in the intermyofibrillar
glycogen located between the myofibrils close to sarcoplas-
mic reticulum and mitochondria and in the intramyofibrillar
glycogen [73, 74]. It is well known that glycogen correlates
with ability of skeletal muscle capacity to perform prolong
and high-intensity exercise [75]. Skeletal muscles are unable
to produce and release glucose, because they lack the glucose-
6-phosphatase enzyme; thus, muscle glycogen is mainly local
energy deposits for muscle contractions such as exercise.
However, skeletal muscles are able to produce high levels of
lactate, up to 30 mM, through the glycogen shunt and which
can be transported to other tissues such liver and brain as an
energy source.
Brain
The average glycogen content in brain is around 3–12 μmol,
which is much less compared to liver and muscle [76, 77].
Glycogen is very important in brain function such as synaptic
activity, memory formation, sensory stimulation and sleep and
wake cycles [77–79]. Also, glycogen is very important in
protecting the brain function under stress conditions such as
hypoglycaemia [80], hypoxia/ischaemia, exhaustive exercise
[81] and seizures [82]. Further, increased glycogen stores in
astrocytes are able to preserve/protect neuronal function and
viability under hypoglycaemia. It has been proposed that as-
trocytes are able to provide energy to neurons via a mecha-
nism called the glycogen shunt where lactate is produced in
astrocytes and then is used by neurons for their energy
requirements.
Although it was thought that glycogen in astrocytes
through the glycogen shunt supports the activity of neu-
rons, it is well established that neurons have an active
glycogen metabolism, which contributes to tolerance to
hypoxia [83]. Neurons synthesise and degrade small
amounts of this polysaccharide continuously. They do not
use it as an energy store but as a rapid and small, but
constant, source of energy. Glycogen metabolism is able
to generate 3ATP, whilst 2ATP is generated from the free
glucose. Also, neurons through transmitters and
neuromodulators stimulate the mobilisation of the astrocyte
glycogen stores, which are converted to lactate to be taken
up and utilised by neurons [84, 85]. Glycogen accumula-
tion in neurons during aging is an evolutionarily conserved
process from flies to mammals, and Laforin disease
resulting from rare mutations in malin and laforin increases
the rate of this process [86]. Laforin is a phosphatase of
glycogen synthase that can directly bind glycogen through
a carbohydrate-binding domain as well as other glycogen
metabolising proteins [17]. Malin is an E3-ubiquitin ligase
that is recruited to its substrates through the interaction with
Laforin [17]. Furthermore, Laforin and malin form a com-
plex, and with the glycogenolytic enzymes, glycogen
debranching enzyme 1 (AGL1) and brain isoform glycogen
phosphorylase orchestrate the degradation of the
polyglucosan bodies [87]. Brain glycogen or glycogen-like
inclusions accumulate in several pathologies such as Pombe
disease [88], Lafora disease [89], Alzheimer disease [90],
amyotrophic lateral sclerosis [91] and adult polyglucosan
body disease [9].
The mutations in genes involved in glycogen metabolism
lead to glycogen storage diseases, which affect primarily the
liver, skeletal muscle, heart and the central nervous system
and kidneys. Glycogen storage diseases are classified accord-
ing to their individual enzyme deficiency, each of which en-
zyme regulates synthesis or degradation of glycogen.
These data indicate that the complexity of glycogen
metabolism at a tissue level and key issues are whether
tumours and their metastases reflect their tissue of origin
or destination or adopt different components for maximum
survival in stress conditions.
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Methods for assessing glycogen stores and turnover
Several techniques have been described for detecting
and assessing the level of glycogen in cells, tissues
and entire organs, such as electron microscopy, immu-
nohistochemical, biochemical, live fluorescence imaging
and radioisotope methods.
Electron microscopy is the only technique able to show
in detail the fine structure of the cell and its various com-
partments. The fine structure of glycogen was first de-
scribed by Revel and colleagues in 1960, as roughly cir-
cular granules from 150 to 400 A in diameter [92]. Today,
electron microscopy is a powerful tool to analyse glycogen
within the cell and its localisation. However, due to the
lack of expertise, cost-effectiveness and time effectiveness,
this technique cannot be used routinely. Routinely, the
presence of glycogen can be examined histochemically in
both cryosections and formalin-fixed, paraffin-embedded
sections by the periodic acid-Schiff (PAS) reaction [93].
Glycogen subcellular distribution can be studied by immu-
nohistochemistry and immunofluorescent techniques by
using a specific antibody against glycogen [94–96], which
was developed by Dr. Baba [97]. Notably, it is very im-
portant to maintain optimal preservation of glycogen in
biopsies. Up to 70 % of glycogen can be lost using for-
malin fixation, and this is due to the soluble nature of the
predominant form of glycogen in the cytoplasm [98].
Three biochemical methods have been used for anal-
ysis of glycogen content in tissue homogenates: (i) acid
hydrolysis of the tissue followed by enzymatic analysis
of glucose, (ii) enzymatic hydrolysis with amylo-α-1,
4-α-1,6-glucosidase followed by analysis of glucose
and (iii) analysis of glucose-1-P produced by degrada-
tion of glycogen with phosphorylase and debranching
complex [99].
The 2-NBDG is a fluorescent glucosamine derivative
that enters the cells through glucose transporters, is
phosphorylated by the enzyme hexokinase and cannot
be metabolised through glycolysis but is incorporated
into glycogen granules. Therefore, this probe is suitable
for glycogen quantification and imaging [100]. Howev-
er, this technique is ideal only for in vitro measurements
and cannot be used for glycogen in vivo determinations,
due to the limited tissue penetration of the emitted
green fluorescence. More recently, a new technique has
been developed to detect de novo glycogenesis in tu-
mour cells in culture and in tumour xenografts
in vivo, by using a novel radiotracer, (18)F-N-(meth-
yl-(2-fluoroethyl)-1H-triazole-4-yl)glucosamine (18F-
NFTG) [101]. This technique shows great promise
for future clinical applications, allowing tumour stratifi-
cation according to glycogen content and correlation
with treatment response.
Glycogen metabolism in cancer progression
and microenvironment
Cancer metabolism and the metabolic reprogramming during
the adaptive process of cells within tumour microenvironment
and resistance to anticancer therapies have been well
recognised in the last decade [102]. Genetic factors such as
oncogenes (i.e. MYC) and tumour supressors and microenvi-
ronmental factors such as hypoxia and acidosis could regulate
glycogen metabolism in cancer cells. Further, cancer-
associated fibroblasts are a major component of the tumour
microenvironment and have a major role in cancer progres-
sion by providing cancer cell metabolic intermediates such as
lactate, amino acids, ketone bodies and various signalling
molecules [103, 104]. Glycogen metabolism is so far
uninvestigated in this role. Other stromal cells include im-
mune infiltrates, which have been of great of interest in cancer
progression, invasion and therapy. Apart from early studies on
differential glycogen expression in T and B cells, this remains
to be investigated [105]. Taken together, we hypothesise that
glycogen metabolism is a major energy source within the tu-
mour microenvironment as well as in the tumour and its re-
sponse to chemotherapy and radiation therapy.
Large quantities of glycogen have been described in vari-
ous cancer cell lines such as breast, kidney, uterus, bladder,
ovary, skin and brain cancer cell lines and in particular cells
undergoing neoplastic transformation [106–109]. Glycogen
metabolism was crucial for maintenance in vitro of hepatomas
[110]. Further, a ‘clear cell carcinoma’ represents a small num-
ber of cases in different cancer types, i.e. breast, which are
characterised by high quantities of glycogen, and aggressive
clinical behaviour [111]. Further, to our knowledge, there is no
information available on the prevalence of cancer in glycogen
storage disease patients. The only data available regards to
occurrence of liver adenomas (with occasional development
of carcinomas) in some of the disorders. However, the patho-
genesis of these lesions is unclear, and in some instances, it
has been linked to the simultaneous occurrence of metabolic
derangements [112].
Hypoxia is a hallmark of the tumour microenvironment
and is characterised by low oxygen concentration as a
result of abnormal blood vessels, defective blood perfusion
and limited nutrients. Thus, under hypoxia, cancer cells
must adapt in order to maintain tumour growth. It is well
established that glycogen has a crucial role to promote cell
survival under hypoxic conditions in normal and cancer
cells [113–117]. Pescador et al. [116] showed that hypoxia
increases glycogen accumulation in myotubes, hepatocytes
and hepatoma cells, through hypoxia-inducible factor 1α
(HIF1α) stabilisation. Importantly, the investigators found
that GYS1, UTP:glucose-1-phosphate uridylyltransferase
(UGP2) and 1,4-alpha glucan branching enzyme (GBE1)
were significantly increased after hypoxia conditions.
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Further, by knocking down either HIF1α or GYS1 atten-
uated hypoxia-induced glycogen accumulation, whilst
GYS1 overexpression was sufficient to mimic this effect,
suggesting that GYS1 regulation by HIF1α plays a central
role in the hypoxic accumulation of glycogen [116]. Also,
hypoxia preconditioning protects cells during anoxia whilst
knockdown of GYS1 expression impairs hypoxic precon-
ditioning and protection, suggesting the important role of
glycogen metabolism in acute and chronic hypoxia [116].
Similarly, the study by Shen et al. [32] found that hypoxia
induced accumulation of glycogen 24 and 48 h after exposure.
Further, they found that PPP1R3C induction correlates with a
significant glycogen accumulation in MCF7 cells under hyp-
oxia whilst knockdown of either HIF1α or PPP1R3C attenu-
ated hypoxia-induced glycogen accumulation significantly.
Pelletier et al. [115] established that hypoxia-induced accumu-
lation of glycogen stores are rapidly mobilised in cells that are
starved from glucose, whilst normoxic control cells exhibit a
high rate of cell death following glucose removal. They found
that phosphoglucomutase 1 (PGM1), which converts the
glucose-6-phosphate to glucose-1-phosphate, was upregulat-
ed in hypoxia conditions via HIF1α. Hypoxia induced and
enhanced accumulation of glycogen in PIK3CA mutant in
human ovarian clear cell carcinoma [117]. In particular, the
glycogen synthase 1, dephosphorylation of GYS1, protein
target to glycogen subunit and glycogen content were in-
creased 24 and 48 h after hypoxia conditions [117]. In another
study, we found that GYS1, PYGL, GAA, GBE, PPP1R3B
and PPP1R3C were upregulated in U87MG cell lines under
hypoxia conditions [113].
Glycogen metabolism may have an important role for can-
cer cell survival under nutrient starvation conditions. Protein
target to glycogen subunit PPP1R3C (PTG) protects liver can-
cer cells in the absence of glucose via regulation of oxidative
stress and autophagy, whereas silencing PPP1R3C further
promotes cytotoxicity [33]. Glycogen phosphorylase brain
form (PYGB) was found to be important also in nutrient star-
vation conditions in cancer cell survival. In pancreatic 2-
deoxy glucose resistance cell lines, PYGBwas low suggesting
a reduced rate of glycogen turnover, whilst knockdown of
PYGB in parental cell lines resulted in cell death under 2-
DG treatment [118]. Another study with gastric cancer cell
lines found that PYGB activity and glycogen breakdown were
increased upon serum starvation conditions, resulting in re-
duced apoptosis and cancer cell survival [119].
Downregulation of glucose-6-phosphatase in glioblastoma
cell lines decreased cell viability, invasion and migration as
well as decreased cell survival under 2-deoxy-glucose treat-
ment [120]. This resulted in accumulation of glucose-6-phos-
phate, increased activity of GYS1, downregulation of PYGL
and increased glycogen accumulation [120].
Cancer genomic data has shown that the glycogenic en-
zymes GYS1, GYS2 and GBE1 are upregulated in 18 % in
AML patients and with significantly poor survival outcome
[121]. Knockdown of GYS1 increased activation of AMPK
and decreased growth of leukaemia cells in vitro and in vivo.
Cheng et al. [122] found that Rab25, a small GTPase involved
in endosomal recycling, enhance survival during nutrient
stress by preventing apoptosis via increased Akt activation
and subsequent glucose uptake, glycogen accumulation and
improved cellular bioenergetics. Also, the PhKG1 (the γ-
subunit) of the holoenzyme phosphorylase kinase, involved
in activation of glycogen phosphorylase, has been shown to
be upregulated in several human tumour samples, also in-
volved in tumour progression, angiogenesis and tumour me-
tabolism [123]. This study indicates that PhKG1 could be a
potential target candidate therapy.
Recently, the glycogen debranching enzyme AGL was
shown to have tumour suppressor function in bladder cancer,
and that loss of AGL leads to increased tumour growth in
xenograft models of bladder cancer [124, 125]. Loss of AGL
leads to decrease in normal cellular glycogen with an increase
in abnormal glycogen structures (e.g. limit dextrin) and in-
crease in glucose consumption and lactate production [124].
Lowering AGL enhanced tumour growth by increasing gly-
cine synthesis through increased expression of serine
hydroxymethyltransferase 2 (SHMT2), whilst depletion of
the SHMT2 rescues the effects of tumour growth of bladder
cancer cells without AGL [124]. It is interesting to note here
that the effect of the AGL in tumour growth was independent
of its enzymatic activity, suggesting that AGL has an un-
known non-enzymatic function. Another study found that
hyaluronic acid 2 (HAS2) is the driver of tumour growth of
bladder cancer with low AGL, suggesting a preclinical ratio-
nal for personalised targeting in patients with low AGL ex-
pressing bladder tumours [126]. Recently, Chen et al. found
that metastasis of breast cancer cells to brain exhibit metabolic
reprogramming with a glycogenic future and ability to store
glycogen [127]. In the same study, brain metastases from hu-
man breast cancer patients expressed higher levels of fructose-
1,6-biphosphate and glycogen compared to the breast primary
tumours [127]. This metabolic switch enables cancer cells to
survive under adverse conditions such as glucose deprivation,
suggesting that glycogen metabolism might be a novel target
for brain metastasis from breast cancer.
The accumulation of glycogen granules in renal cancer
cells is a well-known feature of the ‘clear cell’ versus
‘papillary’ phenotypes but has not been developed as a
specific therapy target [128, 129]. HIF-dependent regula-
tion of glycogen synthesis has also been confirmed in the
human renal clear cell carcinoma cell lines RCC4 and
786-O, which are characterised by constitutive HIF1α
and/or HIF2α activation, due to a defect in the tumour
suppressor protein and HIF-negative regulator von
Hippel-Lindau (VHL) [130]. Similarly, it should be inves-
tigated whether altered glycogen metabolism plays any
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role on the development of renal clear cell carcinomas
driven by VHL mutations.
Taken together, all the above studies show that cancer cells
are able to accumulate glycogen as a deposit source of energy
to enable survival under adverse conditions such as hypoxia
and glucose deprivation as well as sustain metastases.
Pharmacological modulators of glycogenmetabolism
The evidence that glycogen metabolism is reprogrammed in
cancer cells indicates that targeting of glycogen metabolism
could represent a new strategy for cancer treatment. Preclini-
cal and clinical studies will be required to identify the best
candidates to target, and the clinical features associated with
glycogen storage disorders can assist in predicting the toxicity
associated with depletion of the different glycogen metabo-
lism enzymes. In particular, GP defects in Hers’ disease pa-
tients are associated with hepatomegaly, growth retardation,
ketotic hypoglycaemia and post-prandial lactic acidosis. How-
ever, despite those, toxicities might have a therapeutic win-
dow and limit toxicities by targeting the liver glycogen phos-
phorylase. In Table 1, the pharmacological modulators and
specific inhibitors of glycogen metabolism are shown.
Lithium (LiCl) is commonly used for the treatment of
mood and bipolar disorder and has recently been evaluated
as an anticancer drug. Lithium treatment can inhibit glycogen
synthesis and decrease glycogen content in cortical cultured
astrocytes [131] and in the rat liver [132]. On the other hand,
lithium treatment stimulates glycogen synthesis/accumulation
and glycogen synthase activity in the rat diaphragm [133] and
in salivary glands of the rat [134]. Lithium is under evaluation
in clinical trial of prostate cancer (clinicaltrials.gov;
NCT02198859). Valproate, a histone deacetylase inhibitor,
increased the glycogen phosphorylase brain isoform and de-
creased glycogen accumulation in the skeletal muscle of
McArdle disease [135]. Valproate is under evaluation in clin-
ical trials of advance cancers in combination with
temsirolimus and bevacizumab (clinicaltrials.gov;
NCT01552434). Also, an antidiabetic and antiobesity agent,
sodium tungstate, increased glycogen synthesis and accumu-
lation in hepatocytes [136, 137]. Further, cardiac steroids (i.e.
bufalin) induced the formation of glycogen-microtubule struc-
tures via a complex process that requires different signalling
pathways [138].
Metformin, an old antidiabetic drug, has been widely used
in cancer research as a potent combinational anticancer thera-
py. However, the mechanism of action in cancer cells is not
very well understood yet. Recently, it was found that metfor-
min depletes glycogen content in myeloid leukaemia cells,
suggesting that metformin might block the synthesis of gly-
cogen and activates the degradation pathways [121]. Another
study found that ionising radiation resulted in accumulation of
glycogen in lung, prostate and breast cancer cell lines, whilst
metformin rescued the accumulation of glycogen and
sensitised the cells to ionising radiation [139]. Metformin is
now been used in various clinical trials in combination with
anticancer therapy. Dichloroacetic acid (DCA) increases he-
patocellular glycogen accumulation through a PI3K-
dependent mechanism that does not involve PKB/Akt and
is, at least in part, different from the classical insulin-
stimulated glycogenesis pathway [140].
Furthermore, specific inhibitors for the rate-limiting en-
zymes for glycogen metabolism would be the best approach
to target this pathway. However, only the glycogen phosphor-
ylase enzyme has been studied as a potential therapeutic target
for type 2 diabetes. GP is the key enzyme that drives glyco-
genolysis and therefore comprises an important target in the
Table 1 Pharmacological modulators and specific inhibitors of glycogen metabolism
Glycogen phosphorylase inhibitors Pharmacological modulators of glycogen metabolism GAA/1,4-α-glucosidase inhibitors
(i) Active site inhibitors Sodium tungstate (increases glycogen synthesis) Acarbose
e.g. DAB Metformin (depletes glycogen) Miglitol
(ii) AMP site inhibitors Lithium (stimulates or inhibits glycogen synthesis) Voglibose
e.g. BAY1807 Valproate (decreases glycogen content)
BAYR3401 Dichloroacetate (increases glycogen accumulation)





(iv) Purine nucleoside site inhibitors
e.g. Olefin derivatives
Four major classes of glycogen phosphorylases inhibitors. Commercially available inhibitors that block the activity of the GAA enzyme. Compounds
which have shown in the literature that modulates glycogen metabolism
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attempt to reduce post-prandial glucose levels by lowering
hepatic glucose production. Extensive reviews on a range of
GP inhibitors and proposed sites of actions have been reported
[12, 13, 49, 141–145]. Binding sites for physiological and
pharmacological ligands have been identified by crystallogra-
phy. The following four major regulation sites have been used
to develop glycogen phosphorylase inhibitors: the catalytic-
active site (C site), nucleotide-binding site (adenosine
monophosphate (AMP) site), purine nucleoside site (P site)
and the indole site (Table 1) [49]. The presence and absence
of an allosteric ligand such as glucose and AMP can influence
the inhibitory activity; thus, researchers need to be careful
when using the glycogen phosphorylase inhibitors.
Active site inhibitors
Glucose analogues such as N-acetyl-β-D-glucosamine and
the bicyclic compound glucopyranose spirohydantoin have
been synthesised; however, these two analogues have lower
affinity for liver than muscle isoforms of GP. The most potent
active site inhibitor of liver glycogen phosphorylase a is
azasugar 1,4-dideoxy-1,4-amino-D-arabinitol (DAB) [146,
147]. DAB is a potent inhibitor of GPa in hepatocytes in both
in the absence and presence of glucagon, with half-maximal
effect at 1–2 μM and greater than 80 % inhibition of glyco-
genolysis at 5–20 μM [15]. DAB is also an indirect inhibitor
of glycogen synthesis [148].
AMP site inhibitors
Ligands of the AMP activator site cause both inactivation and
allosteric inhibition of glycogen phosphorylase a. A pro-drug,
the dihydropyridine derivative (BAY3401), is metabolised to
1,4-dihydropyridine-2,3-dicarboxylate (BAY1807) and binds
to the AMP site and causes the conversion of GPa to GPb in
liver and skeletal muscle [149]. Researchers at Novo-Nordisk
[150], Merck [151] and Sanofi Aventis [152, 153] have iden-
tified several other compounds that bound to the AMP site,
with EC50 values in the nanomolar range. Phthalic acid de-
rivatives bind at the AMP active site and are potent inhibitors
of liver and muscle GPa [150]. Diacid analogues that bind at
the AMP site not only are very potent but also have approxi-
mately tenfold selectivity against liver versus muscle GP in
in vitro assays [151]. Acyl urea derivatives, which bind at the
AMP active site, were discovered as a novel class of inhibitors
for glycogen phosphorylase [153].
Indole carboxamide site inhibitors
There is one indole site to each subunit, and in the native T
state of GPb, the site is occupied by 30 water molecules [13].
This site is referred to as the indole site since almost all inhib-
itors that bind to the site have been based on an indole-2-
carboxamide scaffold. Researchers from Pfizer [154–158],
Merck [159] and AstraZenca [160–162] have identified sev-
eral indole carboxamide site inhibitors. One of these inhibitors
is ingliforib (CP368, 296), which inhibits the GP isoforms
with IC50 values of 52 nM (liver), 150 nM (brain) and
352 nM (muscle).
Purine nucleoside site inhibitors
The purine nucleoside site inhibitors include purines (e.g.
caffeine), flavopiridol, nucleosides (e.g. adenosine) and nu-
cleotides (e.g. AMP, IMP, ATP, NADH and FAD) [12, 13,
49, 50]. Flavopiridol, an antitumour drug and inhibitor of
cyclin-dependent kinases, was identified as a high-affinity
ligand of the purine nucleoside site [163, 164]. Further
olefin derivatives of flavopiridol have been synthesised
with similar potency on glycogen phosphorylase but high
potency in hepatocytes [165].
Targeting components of glycogen metabolism
in cancer and clinical implications
In Fig. 5, a schematic presentation of targeting glycogen me-
tabolism as a combinational strategy for anticancer therapy is
shown. Glycogen metabolism is upregulated after
bevacizumab treatment in glioblastoma U87MG xenograft
model [113]. In particular, the gene expressions of GYS1,
PPP1R3B, PPP1R3C, GBE, PYGL and GAA, together with
the hypoxia marker CA9, found to be significantly upregulat-
ed in U87MG xenografts treated with bevacizumab [113].
Bevacizumab treatment as an angiogenic therapy would in-
crease hypoxia within the tumour and eventually an adaptive
response of cancer cell, e.g. accumulation of glycogen as an
energy deposit. Furthermore, from the in vitro experiments,
the observation that glycogen accumulates under hypoxia
conditions as a mechanism of cancer cell survival suggests
the idea that combinational therapy of targeting glycogen me-
tabolism together with bevacizumab treatment could provide a
potent strategy for anticancer therapies. Targeting PYGL for
cancer therapy would likely have a therapeutic window and
limited side effects.
Similar targeting of the GYS1 could be another potential
anticancer therapeutic approach for limited side effects, since
mice lacking the skeletal muscle GYS1 are functional and
physically active. An antisense approach to target glycogen
synthase 1 in C6 rat glioma cell lines has been described by
Ardourel et al. [166], with great therapeutic value.
Bladder cancer cells with low AGL expression were found
to be more sensitive to glucose deprivation and glycolysis
inhibition by 2-deoxygl-D-glucose [124]. Similarly, another
study found that human pancreatic cancer cell lines with low
levels of glycogen phosphorylase B (PYGB) are more
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sensitive to glucose deprivation conditions, suggesting that
PYGB could be a therapeutic target in those cancers with
limited glucose levels [118]. Moreover, autophagy might sus-
tain the glycogen breakdown; thus, by blocking both path-
ways could provide synergism as anticancer treatment.
Glycogen breakdown supports the pentose phosphate path-
way, which generates nucleotides required for proliferation
and DNA repair, as well as NADPH, which is an important
reducing agent for reactive oxygen species (ROS) scavenging
and nucleotide, amino acid and lipid synthesis. Considering
this major role of glycogen metabolism in the pentose phos-
phate pathway, combination treatment of glycogen inhibition
with DNA damaging agents, ROS generating agents, mito-
chondria inhibition agents and ionising radiation might
be a potent strategy for anticancer treatment. Also, most
of the above molecules involved in glycogen metabo-
lism have not been tested in cancer cell lines to assess
activity or differential effects based on driver mutations
of metabolism.
Conclusions
In conclusion, therefore, glycogenmetabolism has emerged as
a complex pathway intersecting with many key metabolic
pathways including the Krebs cycle, pentose shunt, glycolysis
and lipid biosynthesis. It represents a major store of high-
energy glucose which does not require ATP for activation.
Thus, under stressful conditions, it may be particularly impor-
tant for survival of tumour cells. Since this is regulated in
hypoxia and by so many different kinase pathways, the final
affects will be complex. However, there exists a wealth of
drugs and kinase inhibitors that could be exploited to target
this pathway and it is important to use the most appropriate
screening conditions for their effect. It is most likely that those
representing the microenvironment in vivo, such as low glu-
cose and hypoxia and acidosis, would be key. It would be
important to test these in in vivo models under such stressful
conditions and to try and repurpose drugs that never went into
the disease area for which they were planned. This still
represents a major problem for interactions between ac-
ademia and the pharmaceutical industry, to have access
to these molecules with appropriate possibilities for li-
censing and development.
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Fig. 5 Targeting glycogen metabolism as a strategy in cancer therapy. Targeting glycogen synthase, glycogen phosphorylase, phosphorylase kinase and
glycogen target subunits as well as other players in glycogen metabolism could enhance anticancer therapy
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